Compare Incyte Corporation (INCY) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Carparts.Com Inc — how do they compare? Incyte Corporation trades at $117.54 (market cap $23.11B), while Carparts.Com Inc trades at $4.89 (market cap $41.22M). The key difference: Incyte Corporation is far larger — about 560.7× Carparts.Com Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| INCY | PRTS | |
|---|---|---|
Market Cap | $23.11B | $41.22M |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $11.40 |
52-Week Low | $67.38 | $3.88 |
Enterprise Value | $19.13B | $56.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
PRTS trades at $4.97, down 6.23% today, following a 10:1 reverse stock split effective May 26, 2026, which helped it regain Nasdaq compliance. The company reported a Q1 2026 adjusted EBITDA beat and secured a $25 million credit facility in June 2026. Revenue has declined from $676M in 2023 to $548M in 2025, with net losses widening to -$50M. Analyst sentiment is positive with 60% buy ratings, but negative cash flow and profitability metrics highlight operational challenges.
The outlook remains cautious due to persistent losses and revenue contraction, though cost-cutting and new financing provide some stability. Investment opportunity lies in potential turnaround execution and low P/S of 0.06, but risks include cash burn, competitive pressures, and reliance on external funding. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
